Low circulating adropin, a hormone regulating metabolic and neurological function, correlates with cognitive decline in aging primates. This identifies a measurable biomarker for identifying individuals at risk of learning and memory dysfunction before clinical symptoms emerge.
Key Points
- Adropin deficiency predicts learning-dependent cognitive decline in aged primates
- Circulating adropin levels distinguish cognitively resilient from vulnerable aging individuals
- Early biomarker detection enables intervention before cognitive deterioration manifests
Longevity Analysis
Adropin operates at the intersection of energy metabolism and neural function—two systems whose decline defines aging. The ability to detect adropin deficiency before cognitive symptoms appear shifts the landscape from reactive management of decline to prospective identification of those requiring support. In aging populations, where cognitive performance determines both quality of life and independence, a circulating biomarker that precedes functional loss creates an opportunity to address the metabolic substrate of cognition before neurological compensation becomes insufficient.
Original published by Nature - npj Aging, by Andrew A. Butler.